抗凝联合牡丹叶治疗卵巢肿瘤合并血栓的临床效果研究

Clinical Study on the Effect of Anticoagulation Combined with Peony Leaf Treatment for Ovarian Tumors with Thrombosis

目的 评价抗凝联合牡丹叶治疗卵巢肿瘤合并血栓的临床疗效。方法 选择2020年1月—2023年12月新泰市中医医院收治的120例卵巢肿瘤合并血栓患者,根据治疗方式的不同将患者进行分组,每组60例,对照组接受西医规范方案治疗,研究组在对照组的基础上联合牡丹叶治疗。主要评估指标包括肿瘤抑制率、凝血指标、不良反应。结果 治疗后,研究组的肿瘤抑制率相比对照组增加,但差异无统计学意义(P>0.05)。研究组的腹水量与对照组比较,差异无统计学意义(P>0.05)。治疗前,两组的生物指标比较,差异无统计学意义(P>0.05)。治疗后,研究组的凝血指标相较于对照组更低,差异有统计学意义(P均<0.05)。对照组不良反应发生率为20.00%,相较于研究组的5.00%更高,差异有统计学意义(χ^(2)=6.176,P<0.05)。结论 牡丹叶联合规范西医方案治疗卵巢肿瘤合并血栓患者能够有效缓解患者症状,不良反应较少。

Objective Evaluate the clinical efficacy of anticoagulation combined with peony leaf treatment for ovarian tumors with thrombosis.Methods A total of 120 patients with ovarian tumor complicated with thrombosis admitted to Xintai Hospital of Traditional Chinese Medicine from January 2020 to December 2023 were selected.The patients were divided into groups according to different treatment methods,with 60 cases in each group.The control group was treated with standardized western medicine.The study group was treated with surgery on the basis of the control group.The main evaluation indicators include tumor inhibition rate,coagulation index and adverse reactions.Results After treatment,the tumor inhibition rate of the study group was higher than that of the control group,but the differ-ence was not statistically significant(P>0.05).There was no significant difference in the amount of ascites between the study group and the control group(P>0.05).Before treatment,there was no significant difference in biological indica-tors between the two groups(P>0.05).After treatment,the coagulation index of the study group was lower than that of the control group,and the difference was statistically significant(all P<0.05).The incidence of adverse reactions in the control group was 20.00%,which was higher than 5.00%in the study group,and the difference was statistically significant(χ^(2)=6.176,P<0.05).Conclusion Peony leaf combined with standardized Western medicine treatment can effectively alleviate symptoms and have fewer adverse reactions in patients with ovarian tumors and thrombosis.